BioNxt Solutions (TSE:BNXT) has released an update.
BioNxt Solutions Inc. announces significant progress in its sublingual Cladribine program for Multiple Sclerosis treatment, highlighting its potential advantage for patients with difficulty swallowing. The company has reported positive results from preclinical studies and plans a human bioequivalence study in early Q1 2025. Additionally, a comprehensive patent application for sublingual anticancer drugs has received a positive international examination report by the EPO.
For further insights into TSE:BNXT stock, check out TipRanks’ Stock Analysis page.